Company Active LTD

Company profile

Affimer Limited

Home | Avacta Life Sciences Limited

We develop safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer and pre|CISION platforms

CRN
08458974
Founded
2013
Age
13

Overview

Legal name
AFFIMER LIMITED
Region
Unknown
Registered address
SCALE SPACE WHITE CITY IMPERIAL COLLEGE CAMPUS
58 WOOD LANE
LONDON
ENGLAND
W12 7RZ
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

2 levels 1 ultimate controller
1
Company Active LTD
Affimer Limited
CRN 08458974
2
Direct controller Active LTD
3
Ultimate controller Active PLC
Avacta Group PLC
CRN 04748597

Company events

Reference milestones and recent Companies House filing stream events.

7 events
29 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

15 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

07 Oct
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzODU0NzAxM2FkaXF6a2N4

Published 07 Oct 2024 06:38

04 Oct
2024

Change Registered Office Address Company With Date Old Address New Address

Address

AD01 | Transaction MzQzODQ1MDg5NWFkaXF6a2N4

Published 04 Oct 2024 04:11

25 Mar
2013

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2014
Funded years
2014
Age at first award
1 years

Projects

2014 GRD Proof of Concept

Affimers: a novel biotherapeutic platform for the treatment of cancer

1 Jun 2014 to 31 Aug 2016

Awarded
£35,647
Total cost £59,411

Promexus is a new biotechnology company which will be developing a novel human therapeutic protein (the Affimer) that will address some of the shortcomings of the current antibody based drugs. Antibodies have been very successful at treating a wide range of human disease such as asthma, arthritis and cancer, but they are expensive to produce and because o...

Product types

GRD Proof of Concept